Showing results (31-40 of 48) with videos related to
Sort By:
Pageof 5
Journal of Neuro-Oncology|February 28, 2023
Outcomes of intraventricular 131-I-omburtamab and external beam radiotherapy in patients with recurrent medulloblastoma and ependymomaKathryn R Tringale, Suzanne L Wolden, Matthias Karajannis, et al.International Journal of Radiation Oncology, Biology, Physics|October 1, 2013
A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancerMatthew G Fury, Nancy Y Lee, Eric Sherman, et al.Head & Neck|March 19, 2015
Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinomaMatthew G Fury, Han Xiao, Eric J Sherman, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 12, 2023
The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patientsAudrey Mauguen, Ravinder K Grewal, Finn Augensen, et al.The Lancet. Oncology|June 20, 2018
Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trialMark M Souweidane, Kim Kramer, Neeta Pandit-Taskar, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 10, 2012
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancerMatthew G Fury, Eric Sherman, Donna Lisa, et al.Plos One|June 6, 2017
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumorsOren J Becher, Nathan E Millard, Shakeel Modak, et al.Clinical Breast Cancer|February 12, 2014
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerKomal Jhaveri, Sarat Chandarlapaty, Diana Lake, et al.Neuro-Oncology|February 19, 2025
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG)Mark M Souweidane, Evan D Bander, Pat Zanzonico, et al.Pediatric Blood & Cancer|September 1, 2024
Craniospinal irradiation and/or intraventricular radioimmunotherapy after high-dose chemotherapy and autologous stem cell rescue in patients with CNS retinoblastoma-Safety and outcomesSameer Farouk Sait, Nancy A Kernan, Elizabeth Klein, et al.Pageof 5